|
Synonyms: AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
aflibercept is an approved drug (FDA (2011), EMA (2012))
Compound class:
Peptide or derivative
Comment: Alfibercept is a fusion protein combining the Fc portion of human IgG with the ligand binding domains of the VEGRF1 and VEGRF2 receptors.
Biosimilars: Patent protection for originator alfibercept is expected to expire earliest in Japan and China (2022), then in US (2023, if Regeneron's extended patent claims are accepted) and the EU (2025), and biosimilar development is underway [3]. Examples include Momenta Pharmaceuticals/Mylan's M710, Alteogen's ALT-L9 (a heat stabilised formulation with a predicted longer shelf-life than Eylea; NCT04058535), and Formycon/Santo Holdings' FYB203. |
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (FDA (2011), EMA (2012)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8739 | aflibercept |
| Synonyms |
| AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 214 |
Reactome Drug
|
R-ALL-9679475 |
|
Reactome Reaction
|
R-HSA-9679477 |
| Other databases | |
| CAS Registry No. | 862111-32-8 |
| ChEMBL Ligand | CHEMBL1742982 |
| DrugBank Ligand | DB08885 |
| GtoPdb PubChem SID | 178103392 |
| PubChem SID | 135347926 |
| Search PubMed clinical trials | aflibercept |
| Search PubMed titles | aflibercept |
| Search PubMed titles/abstracts | aflibercept |
| Wikipedia | Aflibercept |
